From the publishers of JADPRO

Bone Protection Resource Center


Postmenopausal Patient With ER+ Early-Stage Breast Cancer: Bone Protection and Shared Decision-Making

Last Updated: Tuesday, May 16, 2023

Diagnosis and Treatment

A 69-year-old woman presents with an abnormal mammogram to a breast surgeon at her local hospital. She undergoes a left breast biopsy, which shows infiltrating ductal carcinoma. Further testing reveals T2N0M0 ER/PR-positive HER2-negative, Oncotype DX low (9) disease. She undergoes lumpectomy followed by radiotherapy and begins a planned 5-year course of anastrozole.

Bone Protection Therapy and Shared Decision-Making

Per NCCN Guidelines regarding patients with breast cancer who take an aromatase inhibitor,1 her oncologist orders a baseline bone density scan, and results show a T-score of -1.4 in the lumbar spine, and -1.6 in the right hip. He also checks her vitamin D level, which is low at 27 ng/mL. The oncologist discusses the importance of maintaining bone health with the patient. Even though she has not yet developed osteoporosis (defined as a T-score of < -2.5),2 she is at risk for further bone loss due to age and her prescribed aromatase inhibitor.

After a shared decision-making discussion, the oncologist and patient agree that she will start on a bone-modifying agent (BMA) to reduce her risk of further bone loss. She chooses to start denosumab at a dose of 60 mg every 6 months as a subcutaneous injection, as she does not want infusion therapy and this treatment aligns with her office visits for follow-up.

She begins the denosumab treatment after both a routine dental care evaluation to ensure she is not at increased risk for osteonecrosis of the jaw (ONJ) and a patient education meeting with her oncology clinical pharmacist to review side effects and a monitoring plan. She also begins a daily calcium/vitamin D supplement.


After starting the BMA, the patient has checkups every 6 months to monitor her vitamin D and calcium levels and to evaluate for complications such as ONJ. During these office visits, she also receives her denosumab injections and has a follow-up visit with her care team, alternating between her medical oncologist and nurse practitioner.

She also undergoes a bone density scan every 2 years to evaluate change and response to the bone agent. Her first bone density scan 2 years after starting treatment shows an improved T-score of -1.3 in both the lumbar spine and hip. Now that she is no longer at high risk for osteoporosis, she stops taking the denosumab and begins taking an oral bisphosphonate to prevent osteoporosis.


A bone density scan score of -1.0 to -2.5 indicates that a patient has osteopenia and may be at risk for developing osteoporosis.2 This patient had a score of -1.4 and is postmenopausal, so per NCCN guidelines for ER-positive early-stage breast cancer, she was placed on anastrozole for 5 years for treatment of her breast cancer.1 Denosumab at a dose indicated for osteoporosis was started given her high risk for progression from osteopenia to osteoporosis while on an aromatase inhibitor. This is different than the dosing for prevention of skeletal-related events in metastatic breast cancer (120 mg every 4 weeks).3,4 Clinical judgment and patient engagement shared decision-making were pivotal to this plan. Careful prescription, monitoring, and management of BMAs in practice for individuals with breast cancer is a collaborative effort in which oncology APPs, including pharmacists, nurse practitioners, and physician assistants, all play a crucial role.


  1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer Version 2.2023. Published February 7, 2023.
  2. Shapiro CL. Management of osteoporosis in women with breast cancer. Breast Cancer Manag. 2020;9.
  3. Xgeva (denosumab) prescribing information. 2010.
  4. Prolia (denosumab) prescribing information. 2010.

Test your knowledge of optimizing bone protection in patients with breast cancer

Last Updated: Tuesday, May 16, 2023
News & Literature Highlights


Breast Cancer with Bone Metastasis: Molecular Insights and Clinical Management

Current Osteoporosis Reports

Updates in Management of Bone Metastatic Disease in Primary Solid Tumors with Systemic Therapies

JAMA Network Open

Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy

Journal of the National Comprehensive Cancer Network

Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non–Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors

Annals of Pharmacotherapy

Impact of Extended-Interval Versus Standard Dosing of Zoledronic Acid on Skeletal Events in Non–Small-Cell Lung Cancer and Small-Cell Lung Cancer Patients With Bone Metastases

JAMA Open Network

Description of Major Osteoporotic Fractures in Women With Invasive Breast Cancer Who Received Endocrine Therapy

JAMA Open Network

Evaluation of Frequency of Administration of Intravenous Bisphosphonate and Recurrent Skeletal-Related Events in Patients With Multiple Myeloma

Journal of Bone Oncology

Bone Metastases From Urothelial Carcinoma. The Dark Side of the Moon


Effect of antiresorptive therapy on aromatase inhibitor induced bone loss in postmenopausal women with early-stage breast cancer: A systematic review and meta-analysis of randomized controlled trials

Journal of Clinical Oncology

Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: ASCO-OH (CCO) guideline update